Ollin's $330M War Chest Targets a New Standard in Vision Care

AUSTIN, TX – June 24, 2026 – In a move that sends a clear signal to the titans of the ophthalmology market, clinical-stage biotech firm Ollin Biosciences has announced an oversubscribed $330 million Series B financing. The staggering sum, secured just a year after the company’s 2023 launch, provides a formidable war chest to advance its lead candidate, OLN324, a next-generation therapy for vision-threatening retinal diseases, into pivotal late-stage trials.

This financing isn't just another funding announcement; it's a calculated, high-stakes bet on disrupting a $15 billion arena dominated by pharmaceutical giants like Roche and Regeneron. The proceeds will primarily fuel global Phase 3 trials for OLN324 in diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), two of the leading causes of blindness in adults. The funding also earmarks resources to advance a second novel therapy, OLN102, for thyroid eye disease (TED) into clinical development, showcasing a strategic vision that extends beyond a single asset.

A Calculated Bet in a Crowded Market

The sheer size and oversubscribed nature of the round are particularly noteworthy in a biotech funding environment that has grown increasingly selective. Since the market correction of 2022, venture capitalists have prioritized companies with de-risked assets and clear clinical data. Ollin, with its promising head-to-head trial results, fits that bill perfectly, attracting a syndicate of the industry’s most sophisticated investors.

The round was co-led by new investor TCGX, a firm known for its science-driven, long-term “patient capital” approach, and founding investor ARCH Venture Partners, a powerhouse in building companies from breakthrough science. The participation of crossover funds, sovereign wealth funds, and other blue-chip VCs—including a16z Bio+Health, Blackstone Multi-Asset Investing, and CPP Investments—underscores broad confidence in Ollin’s strategy and technology.

“We founded Ollin to challenge the status quo in ophthalmology,” said Jason Ehrlich, M.D., Ph.D., Co-founder and Chief Executive Officer of Ollin Biosciences. “Their support reflects confidence in the strength of our scientific rationale and clinical data, the significant commercial opportunity... and the differentiated clinical profile we believe OLN324 can offer physicians and patients.”

This sentiment was echoed by the firm's new board member from TCGX. “Ollin is advancing product candidates that have the potential to significantly change the treatment paradigm in vision-threatening diseases,” said Cariad Chester, Managing Partner of TCGX. “In a randomized, head-to-head study, OLN324 generated compelling clinical data that we believe positions OLN324 as a best-in-class therapy.”

The Science of Sight: Differentiating in a $15 Billion Arena

Ollin isn’t just entering the market; it’s aiming to redefine it. The current standard of care for DME and wAMD revolves around anti-VEGF therapies like Regeneron's Eylea and Roche's Vabysmo. While effective, these treatments leave room for improvement in efficacy, durability, and patient outcomes. OLN324 is engineered to raise that bar.

Building on the success of dual-target therapies, OLN324 is a next-generation bispecific antibody that inhibits both VEGF and Angiopoietin-2 (Ang2), two key drivers of the vascular leakage and instability that characterize these diseases. The company claims its candidate possesses substantially higher Ang2 potency than its direct competitor, Vabysmo, along with an increased molar dose and a smaller protein format, which may improve tissue penetration.

The early clinical data from the 164-patient JADE study provides the foundation for this optimism. In a head-to-head comparison with Vabysmo, OLN324 demonstrated what the company calls “meaningfully faster and greater” improvements. In DME patients, for instance, those on the higher dose of OLN324 saw a 75% greater improvement in retinal drying at week one. By week 12, nearly 90% of these patients had achieved an absence of DME, compared to 57% in the Vabysmo arm. These anatomical improvements were accompanied by numerically greater gains in vision.

Critically, the therapy also showed a favorable safety profile, with zero cases of intraocular inflammation—a nagging concern with some existing treatments. While the JADE study was a smaller, earlier-phase trial, its results were compelling enough to secure both the financing and a clear path forward from the FDA and European Medicines Agency for the Phase 3 program, slated to begin in late 2026.

Building a Pipeline Beyond a Single Asset

Smart investors rarely bet on a single horse, and Ollin’s strategy reflects this. The Series B funding also propels OLN102, a first-in-class candidate for thyroid eye disease (TED), into the clinic. TED is a debilitating autoimmune condition where the current market is dominated by a single approved therapy, Tepezza. While a breakthrough, Tepezza requires inconvenient intravenous infusions and has been linked to side effects like hearing impairment, creating a clear opening for a better alternative.

OLN102 employs a novel bispecific antibody approach, targeting both the TSHR and IGF-1R receptors implicated in the disease. By inhibiting both pathways, Ollin believes its therapy could offer superior safety and efficacy. Furthermore, OLN102 has the potential to address the underlying autoimmune dysfunction of Graves' disease, which is the root cause of TED in most patients—a truly disease-modifying approach that could set a new therapeutic standard.

Navigating the Path from Lab to Market

With $330 million in the bank, Ollin is well-capitalized to navigate the expensive and lengthy Phase 3 trial process. The company's rapid ascent is a testament to its focused, asset-centric model and the deep industry expertise of its leadership team. CEO Jason Ehrlich’s previous role at Genentech, where he was involved in the development of Vabysmo, provides him with an intimate understanding of the very market he now aims to disrupt.

This strategic insider knowledge is evident in the company’s decision to run an early head-to-head trial against a market leader, a bold move that provided a swift and clear benchmark of OLN324's competitive potential. The road ahead remains challenging, with a robust pipeline of competitors exploring everything from gene therapies to sustained-release implants. However, by securing a massive financial runway and demonstrating promising early data for two distinct, high-value assets, Ollin Biosciences has firmly established itself as a company to watch in the future of vision care.